EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY™ delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of... | May 19, 2023